A 37-year-old woman presented with a supratentorial cerebral mass, which was diagnosed histologically as a primitive neuroectodermal tumor ... with cerebral PNET at an atypical age, especially ...
Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback